UNSPSC 51313304: Promethazine hydrobromide

This classification denotes a phenothiazine C17H20N2S.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H7Q13127S, chemically known as 10h-phenothiazine-10-ethanamine, n,n,.alpha.-trimethyl-, hbr (1:1), but more generally known as promethazine hydrobromide, which bears US NIH Compound Identifier 56841706. Most nations, for tariff and trade purposes, schedule promethazine hydrobromide under HS 29343090 and SITC 51578. As of Q4 2014, PROMETHAZINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity.

Promethazine hydrobromide bears US NLM identifiers UMLS ID C0982361 and NCI Concept Code C97704. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)N(C)C.BR.

UNSPSC 51313304 Promethazine hydrobromide is a Commodity code that represents a single pharmaceutical product, yet state and local procurement activity under this code shows minimal direct purchasing of the product itself. Instead, recent opportunities reveal that state and local agencies are sourcing pharmaceutical products through broader cooperative purchasing frameworks and specialized procurement mechanisms. The issuing bodies soliciting under this code span state health and human services agencies, county health departments, and multistate cooperative purchasing alliances, rather than a concentrated base of repeat buyers for the specific drug.

Activity appears concentrated in Florida and Minnesota-Oregon procurement networks as of early 2026. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline, supporting quarterly deliveries to the Seminole County Community Health Building with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for establishing state-level pharmacy benefit arrangements outside traditional pharmacy benefit manager relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The MMCAP procurement emphasizes price competitiveness (75 percent of evaluation weight) and establishes a July 1, 2026 effective date for awarded contracts.